Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lipids changes in liver cancer.

Jing-Ting Jiang1, Ning Xu, Xiao-Ying Zhang

  • 1Department of Tumor Biological Treatment, the Third Affiliated Hospital, Suzhou University, Changzhou, China. jjtnew@163.com

Journal of Zhejiang University. Science. B
|June 15, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mediation effects of age, intramuscular adipose tissue index and serum albumin on survival status in initial dialysis patients.

Renal failure·2025
Same author

J-Shaped Relationship of the Triglyceride-Glucose Index with All-Cause Mortality in Initial Hemodialysis Patients in China: A Multicenter, Retrospective Cohort Study.

Blood purification·2025
Same author

XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.

Signal transduction and targeted therapy·2024
Same author

Clinical significance of IFIT2 expression in human renal cancer tissues.

Translational cancer research·2022
Same author

Would foot arch development in children characterize a body maturation process? A prospective longitudinal study.

Biomedical journal·2021
Same author

LncRNA <i>HCG18</i> suppresses CD8<sup>+</sup> T cells to confer resistance to cetuximab in colorectal cancer via miR-20b-5p/PD-L1 axis.

Epigenomics·2021

Liver cancer disrupts lipid and lipoprotein metabolism, impacting energy homeostasis. This review explores the clinical significance of these metabolic changes in liver cancer patients, particularly those with viral hepatitis.

Area of Science:

  • Hepatology
  • Metabolic Research
  • Oncology

Background:

  • The liver is central to energy metabolism, synthesizing key lipids and lipoproteins essential for homeostasis.
  • Liver cancer, a prevalent malignancy often linked to Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infections, significantly impairs liver function.
  • Chronic liver conditions like hepatitis and cirrhosis, frequently preceding liver cancer, exacerbate hepatic dysfunction and alter lipid metabolism.

Purpose of the Study:

  • To review the clinical significance of altered lipid and lipoprotein metabolism in the context of liver cancer.
  • To highlight the impact of impaired liver function on systemic lipid profiles.
  • To connect viral hepatitis infections, a major risk factor, with metabolic disturbances in liver cancer.

Main Methods:

Related Experiment Videos

  • Literature review synthesizing current research on liver cancer and lipid metabolism.
  • Analysis of clinical data and studies examining plasma lipid and lipoprotein patterns in liver cancer patients.
  • Examination of the role of hepatic function and viral infections (HBV, HCV) in metabolic alterations.

Main Results:

  • Liver cancer leads to impaired synthesis and altered patterns of plasma lipids and lipoproteins.
  • Hepatic dysfunction, exacerbated by viral hepatitis and cirrhosis, significantly influences in vivo lipid metabolism.
  • Changes in lipid profiles serve as potential indicators of disease progression and severity.

Conclusions:

  • Altered lipid and lipoprotein metabolism is a critical feature of liver cancer.
  • Understanding these metabolic changes is clinically significant for managing liver cancer patients.
  • Targeting metabolic pathways may offer novel therapeutic strategies for liver cancer.